San Francisco startup Framework Therapeutics can also be working on an oral, after-daily GLP-one drug identified as GSBR-1290—the drug surpassed Wall Avenue’s expectations in June when a mid-stage analyze confirmed typical weight loss of all over six% and it plans to start An additional mid-phase demo toward the tip of the 12 months—that foun